Tumours derived from ezrin-deficient cells demonstrated a significant reduction in lymphangiogenesis compared to MDASrc cells, as indicated by lymphatic vessel markers lyve-1 and podoplanin (Figure 3E and F, respectively). Here, LYVE1 is linked to neoplasm.